Trial Profile

COVALENT-211: Phase IIb trial of Icovamenib in severe insulin-deficient type 2 diabetes patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icovamenib (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms COVALENT-211

Most Recent Events

12 Jan 2026 According to a Biomea fusion media release, data readout of the 26-week primary endpoint is expected in Q4 2026.
13 Nov 2025 New trial record
05 Nov 2025 According to a Biomea fusion media release, first Patient In ("FPI") expected in the first quarter of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com